At RPRD, our team of experts lead in the implementation and advancement of precision medicine. Their decades of experience developing innovative solutions in medical genetics and their thoughtful consultancy guides clinicians, researchers, and drug developers as they implement and advance precision medicine in their fields.
Ulrich Broeckel, MD
Founder & Chief Executive Officer
Ulrich Broeckel, MD, is a leading physician-scientist with over 20 years of experience in genetics and genomics and more than 10 years of experience in clinical diagnostics. He is an expert in translational pharmacogenomics research and is a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the NIH initiatives on clinical pharmacogenomics. Dr. Broeckel also serves as Professor of Pediatrics, Section Chief of Genomic Pediatrics, and Associate Director for Pharmacogenomics, Genomic Sciences, and Precision Medicine Center at the Medical College of Wisconsin. Read more about Dr. Broeckel and his research team’s scientific achievements and research interest.
Gunter Scharer, MD, PhD
Chief Medical Officer & Medical Director
Gunter Scharer, MD, is a board-certified medical geneticist with 15+ years of clinical and laboratory experience. He is board certified in Clinical Genetics, Clinical Molecular Genetics, and Medical Biochemical Genetics, and licensed to practice in multiple states. Dr. Scharer is a renowned geneticist with deep experience in rare disorders and mitochondrial disease. He is a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Pharmacogenomics Research Network (PGRN). Prior to joining RPRD, Dr. Scharer was the director of the Department of Medical Genetics and Genomics at Children’s Minnesota and Adjunct Associate Professor in Pediatrics at the Medical College of Wisconsin.
Amy Turner, MS
Director, Operations and Innovation
Amy is a leading scientist with over 10 years of experience in pharmacogenomics and precision medicine translational research. She is responsible for RPRD’s cutting-edge method development and lab operation. Amy is an active participant of the PharmVar Consortium and serves as a Gene Expert Panel member. She leads multiple collaborative projects with academic institutions, healthcare organizations, and drug developers to further all pharmacogenomics applications. Amy’s awareness of technological trends coupled with her extensive insight into the dynamic pharmacogenomics landscape allows her to provide RPRD clients with the most advanced pharmacogenomics consultation available. She received her Master of Science in Pharmacogenomics from Manchester University, Indiana.
Andrea Matter, MS
Director, Regulatory Affairs
Andrea leverages over a decade of experience in clinical diagnostics, specializing in CLIA/CAP compliance, quality management, and GMP documentation. She provides consultation to RPRD clients on all of their compliance needs, ranging from patient privacy (HIPPA) and safety for healthcare management to understanding FDA guidelines. Andrea understands that robust quality standards and continuous improvement are the keys to providing RPRD clients with superior pharmacogenomics results. Testing accuracy and patient safety is always her top priority.
Praful Aggarwal, MS
Praful is a bioinformatics expert in pharmacogenomics data analysis, clinical interpretation and reporting with 9+ years of experience. His in-depth knowledge of data analysis, translation and reporting, using various cutting-edge genetic analysis platforms, enables him to provide complete informatics and consulting services in a wide range of applications, including clinical implementation, scientific research, and drug development. He integrates the latest clinical guidelines into bioinformatics solutions to help clients achieve their goals for knowledge-based pharmacogenomics implementation.
Board of Directors
Ulrich Broeckel, MD – Founder and CEO
Ulrich Broeckel, MD, is a leading physician-scientist with over 20 years of experience in genetics and genomics and more than 10 years of experience in clinical diagnostics. He is an expert in translational pharmacogenomics research and is a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the NIH initiatives on clinical pharmacogenomics.
Carter Cliff – Co-Founder
Carter Cliff is Founder & CEO of Vascugen, a company committed to developing treatments for patients suffering from incurable diseases including the leading cause of limb amputation. Previously he co-founded Opsis Therapeutics with the goal to reverse blinding disorders of the retina, which led to a Strategic R&D Alliance with BlueRock Therapeutics. A serial entrepreneur, Carter co-founded RPRD Diagnostics to market ethnicity-inclusive precision medicine.
Susan Slocum, MBA
Susan Slocum has over 30 years experience in investment management with more than 25 years in health care investment management. She currently serves as Treasurer & Investment Officer for Children’s Hospitals and Clinics of Minnesota, one of the 10 largest pediatric systems in the United States. Sue has achieved top 15th percentile returns on an endowment investment portfolio over 5 years ending June 30, 2018 as CIO of the seventh-largest pediatric health care system. She has managed $1.4 billion in invested assets and an additional $1.7 billion in multi-employer union pension plan.